Physician profile
Michael Jerome
NPI 1306164967
$734.85
in general payments reported to CMS, 2019-2025
13 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $99.95 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.00 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $150.50 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $120.86 | 2024-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.38 | 2024-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $59.91 | 2024-2025 | Rybelsus, Ozempic |
| Alk-Abello, INC | $58.12 | 2025 | Neffy |
| Amgen INC. | $55.01 | 2025 | Otezla, Repatha |
| Pfizer INC. | $30.00 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $29.76 | 2025 | Zoryve |
| Lilly USA, LLC | $29.45 | 2025 | Mounjaro, Zepbound |
| Eisai INC. | $27.69 | 2025 | |
| Soleno Therapeutics, INC. | $25.34 | 2025 | Vykat Xr |
| Glaxosmithkline, LLC. | $21.10 | 2025 | Pediarix, Bexsero, Rotarix |
| Dexcom, INC. | $19.73 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jerome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.